Bao Y, Pan Y, Taylor A, Radakrishnan S, Luo F, Pincus HAlan, Schackman BR.
2016.
Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians.. Health Aff (Millwood). 35(6):1045-51.
McDonough TL, Paolicchi JM, Heier LA, Das N, Engel M, Perlman JM, Grinspan ZM.
2017.
Prediction of Future Epilepsy in Neonates With Hypoxic-Ischemic Encephalopathy Who Received Selective Head Cooling.. J Child Neurol. 32(7):630-637.
McDonough TL, Paolicchi JM, Heier LA, Das N, Engel M, Perlman JM, Grinspan ZM.
2017.
Prediction of Future Epilepsy in Neonates With Hypoxic-Ischemic Encephalopathy Who Received Selective Head Cooling.. J Child Neurol. 32(7):630-637.
Lee J, Wanyan T, Chen Q, Keenan TDL, Glicksberg BS, Chew EY, Lu Z, Wang F, Peng Y.
2022.
Predicting Age-related Macular Degeneration Progression with Longitudinal Fundus Images Using Deep Learning.. Mach Learn Med Imaging. 13583:11-20.
Hildick-Smith GJ, Pesko MF, Shearer L, Hughes JM, Chang J, Loughlin GM, Ipp LS.
2015.
A Practitioner's Guide to Electronic Cigarettes in the Adolescent Population.. J Adolesc Health. 57(6):574-9.
Press MJ, Gerber LM, Peng TR, Pesko MF, Feldman PH, Ouchida K, Sridharan S, Bao Y, Barron Y, Casalino LP.
2015.
Post-Discharge Communication Between Home Health Nurses and Physicians: Measurement, Quality, and Outcomes.. J Am Geriatr Soc. 63(7):1299-305.
Press MJ, Gerber LM, Peng TR, Pesko MF, Feldman PH, Ouchida K, Sridharan S, Bao Y, Barron Y, Casalino LP.
2015.
Post-Discharge Communication Between Home Health Nurses and Physicians: Measurement, Quality, and Outcomes.. J Am Geriatr Soc. 63(7):1299-305.
Press MJ, Gerber LM, Peng TR, Pesko MF, Feldman PH, Ouchida K, Sridharan S, Bao Y, Barron Y, Casalino LP.
2015.
Post-Discharge Communication Between Home Health Nurses and Physicians: Measurement, Quality, and Outcomes.. J Am Geriatr Soc. 63(7):1299-305.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..
2019.
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..
2019.
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..
2019.
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling LA, Dittus C, Chen Z, Huang X et al..
2019.
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.. Blood. 133(11):1201-1204.
Cea ME, M Reid C, Inturrisi C, Witkin LR, Prigerson HG, Bao Y.
2016.
Pain Assessment, Management, and Control Among Patients 65 Years or Older Receiving Hospice Care in the U.S.. J Pain Symptom Manage. 52(5):663-672.